Summary
The presence of excessive amounts of advanced glycation end products (AGE) in tissues or in the circulation may critically affect the progression of diabetic nephropathy. Circulating AGE levels, mainly in the form of small peptides, increase in diabetic patients or in patients with end-stage renal disease. This rise correlates with the severity of the nephropathy. However, so far little is known about the fate of AGE-proteins and AGE-peptides in renal tissue, and in order to elucidate this issue we undertook the present study. AGE-bovine serum albumin (AGE-BSA) and AGE-peptides were prepared, characterized by spectrophotometry, spectrofluorometry, chromatography and SDS-PAGE. AGE-peptides reacted in vitro with LDL producing biochemical and ultrastructural modifications. Using colloidal gold post-embedding immunoelectron microscopy with an anti-AGE antibody generated in our laboratory, we followed, in a short-term kinetic study, the cellular and sub-cellular localisation of circulating AGE-products throughout the nephron. AGE-peptides or AGE-BSA were injected into otherwise normal rats and detected by protein A-gold immuno-cytochemistry after 15, 30 or 45 min of circulation. Most of the AGE- BSA was found in the lumen of capillary vessels and distributed along the endothelial side of the glomerular basement membrane. Presence on mesangial matrix was also apparent. AGE-peptides were easily filtered and actively reabsorbed by the proximal convoluted tubule. At 15 min, little labelling was found in the glomerular wall. Instead, the labelling was present in the urinary space and microvilli of epithelial cells. Early endosomes displayed intense labelling as well. At 45 min, late endosomes and lysosomes added to the pattern of labelling. The distal tubule epithelial cells were devoid of labelling for any of the intervals studied. AGE-peptides but not AGE-BSA could be detected in the urine of injected rats. These observations point to participation of the endo-lysosomal apparatus of the proximal convoluted tubule to the disposal of AGE-peptides, while giving an ultrastructural support for a key role of the kidney in AGE catabolism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- AGE:
-
Advanced glycation end products
- BSA:
-
bovine serum albumin
- BHT:
-
butylated hydroxytoluene
- DEAE:
-
diethyl aminoethyl cellulose
- GBM:
-
glomerular basement membrane
- PBS:
-
phosphate buffered saline
- PMSF:
-
phenylmethylsulphonyl fluoride
- TBS:
-
Tris buffered saline
References
Nathan D (1994) Relation between metabolic control and long-term complications of diabetes. In: Kahn CR (ed) Joslin's Diabetes Lea and Febiger, Philadelphia
Dahl-Jorgensen K, Brinchmann-Hansen O, Bangstad HJ, Hanssen KF (1994) Blood glucose control and microvascular complications — what do we do now? Diabetologia 37: 1172–1177
The Diabetes Control and Complications Trial Data Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977–986
Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491–494
Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50: 385–432
Brownlee M (1994) Glycation and diabetic complications. Diabetes 43: 836–841
Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138–151
Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23: 1–19
Brownlee M, Vlassara H, Cerami A. (1987) The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In: MJC Crabbe (ed) Diabetic complications: scientific and clinical aspects. Churchill Livingston, London p94
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315–1321
Brownlee M (1990) Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr (eds) Diabetes mellitus: theory and practice. Elsevier, New York, pp 279–291
Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87: 432–438
Bucala R, Model P, Cerami A (1984) Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 81: 105–109
Bucala R, Vlassara H, Cerami A (1992) Advanced glycosylation end-products. In: Harding JJ Crabbe, MJC (ed) Post-translational modifications of proteins, vol 2. CRC Press Inc, Boca Raton, pp 53–179
Makita Z, Bucala R, Rayfield EJ et al. (1994) Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 343: 1519–1522
Vlassara H, Fuh H, Makita Z, Krungkrai, Cerami A, Bucala R (1992) Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12043–12047
Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin- AGE: a circulating marker for advanced glycosylation. Science 258: 651–653
Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. New Engl J Med 325: 836–842
Schmidt AM, Mora R, Cao K et al. (1994) The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882–9888
Schmidt AM, Vianna M, Gerlach J et al. (1992) Isolation and characterization of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987–14997
Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and Thrombosis 14: 1521–1528
Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci USA 89: 2873–2877
Horii Y, Skolnik E, Suthanthiran M, Vlassara H (1992) Novel T-cell receptors for advanced glycation endproducts (AGE) mediate production of IFN. Diabetes 41: 59A (Abstract)
Neper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of RAGE: a cell surface receptor for advanced glycation end products of proteins. J Biol Chem 267: 14998–15004
Vlassara H, Moldawer L, Chan B (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1813–1820
Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation endproducts inversely correlates with insulin levels in vivo. Diabetes 37: 456–461
Radoff S, Vlassara H, Cerami A (1988) Characterization of a solubilized cell surface binding protein on macrophages specific for protein modified nonenzymatically by advanced glycosylation endproducts. Arch Biochem Biophys 263: 418–423
Vlassara H, Brownlee M, Cerami A (1986) Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J Exp Med 164: 1301–1309
Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889–9897
Wautier JL, Wautier MP, Schmidt AM et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742–7746
Bucala R, Makita Z, Vega G et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dislipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91: 9441–9445
Deppisch R, Nawroth P (1994) Toxicity of uraemia-does it come of AGE? Nephrol Dial Transplant 9: 1–2
Makita Z, Radoff S, Rayfield EJ, Yang, Z (1991) Clinical assessment and significance of advanced glycation in patients with diabetic nephropathy. New Engl J Med 325: 836–842
Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP (1994) Immunological quantification of advanced glycation end products in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216–222
Mitsuhashi T, Nakayama H, Itch T et al. (1993) Immunochemical detection of advanced glycation end products in renal cortex from streptozotocin-induced diabetic rats. Diabetes 42: 826–833
Kobert SM, Makita Z, Firanek CA, Vlassara H (1993) Advanced glycation end products in continuous ambulatory peritoneal dialysis patients. A J Kidney Dis 22: 588–591
Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem 266: 7329–7332
Gugliucci A, Bendayan M (1995) Reaction of advanced glycation products with renal tissue from normal and streptozotocin-induced diabetic rats. An ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 43: 591–600
Vlassara H, Striker LJ, Teichberg S, Fuh H, Ming LY, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91: 11704–11708
Sell DR, Monnier VM (1990) End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85(2):380–384
Fuh H, Yang D, Striker L, Striker G, Vlassara H (1992) In vivoAGE-peptide injection induces kidney enlargement and glomerular hypertrophy in rabbits: prevention by aminoguanidine. Diabetes 41[Suppl]:9A (Abstract)
Njoroge FG, Sayre LM, Monnier VM (1987) Detection of D- glucose derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohyd Res 167: 211
Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM (1989) Aging of proteins: immunological detection of a glucose derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264: 3758–3764
Njoroge FG, Monnier VM (1989) The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 304: 85–91
Steinbrecher UP (1987) Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262: 3603–3610
Laemmli UK (1970) Cleavage of stuctural proteins during assembly of the head of bacteriophage T4. Nature 227: 680–685
Bjerrum OJ, Schafer-Nielsen C (1986) In: Dun MJ (ed) Analytical electrophoresis. Chemie, Weinheim, p 315
Hammes BD (1981) An introduction to polyacrylamide gel electrophoresis. In: Hammes BD, Rickwood D (eds) Gel electrophoresis of proteins: a practical approach. IRL Press Ltd, London, pp 1–19
Schumaker VN, Puppione D (1986) Sequential flotation ultracentrifugation. Methods Enzymol 128: 155–170
Forte TM, Nordhausen RW (1986) Electron microscopy of negatively stained lipoproteins. Methods Enzymol 128: 442–457
Nakayama H, Taneda S, Kuwajima S et al. (1989) Production and characterisation of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162: 740–747
Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycation end products in vivo. J Biol Chem 267: 5133–5138
Harlow E, Lane D (1988) Immunization. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 53–137
Harlow E, Lane D (1988) Purification and storage of antibodies. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 283–318
Smith P, Krohn R, Hermanson G et al. (1985) Measurement of protein using bicinconinic acid. Anal Biochem 150: 76–85
Bendayan M (1984) Protein A-gold electron microscopic immunocytochemistry: methods, applications and limitations. J Elec Micros Tec 1: 243–270
Bendayan M, Gingras D, Charest P (1986) Distribution of endogenous albumin in the glomerular wall of streptozotocin-induced diabetic rats. Diabetologia 29: 868–875
Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174: 931–939
Dobrian A, Simionescu M (1995) Irreversibly glycated albumin alters the physico-chemical characteristics of low density lipoproteins of normal and diabetic subjects. Biochim Biophys Acta 1270: 26–35
Takahashi M, Ohishi T, Aoshima H et al. (1993) The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 36: 664–667
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gugliucci, A., Bendayan, M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39, 149–160 (1996). https://doi.org/10.1007/BF00403957
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403957